Stay updated with breaking news from Current Prescribing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection Presentation highlights include data for...
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction AUSTEDO is the... | June 10, 2023
UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of... | May 20, 2023
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated up to... | April 28, 2023